Hypha Labs (FUNI) AI Stock Analysis

Top Page

Hypha Labs

(Other OTC:FUNI)

Select Model

Rating:42Neutral

Price Target:$0.03▲(190.91% Upside)

Action:reiterated

Date:02/18/26

The overall score of 42 reflects Hypha Labs' severe financial distress, with no revenue, negative equity, and ongoing cash burn. While there has been some improvement in cash flow, the company's viability remains highly uncertain. Technical indicators show weak momentum, and valuation metrics are unattractive due to persistent losses. The stock carries substantial risk.

Positive Factors

Improving cash-flow trendTTM free cash flow remains negative but shows improvement versus the prior year, indicating management has reduced burn. That trend, if sustained, lowers near-term refinancing pressure and extends runway, offering a more durable path to stability while revenue remains absent.

Negative Factors

Zero revenue run-rateNo reported revenue in the trailing period indicates the company lacks recurring sales or commercial traction. Absent material product commercialization, the firm cannot organically fund operations, making sustained external financing or a strategic pivot necessary for long-term viability.

Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $376.96K
Dividend Yield: ―
Average Volume (3M): 163.22K
Price to Earnings (P/E): -0.2
Beta (1Y): 1.31
Revenue Growth: ―
EPS Growth: 47.23%
Country: US
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Hypha Labs Business Overview & Revenue Model

Company Description

Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate benef...

How the Company Makes Money

null

Hypha Labs Financial Statement Overview

Summary

Income statement shows no revenue and persistent losses (score 5). Balance sheet indicates negative equity and high debt (score 5). Cash flow remains negative but improved (score 10). Overall financial health is precarious.

Income Statement

5Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	2.70M	2.50M
Gross Profit	-23.96K	0	0	0	1.07M	715.16K
EBITDA	-1.47M	-2.95M	-1.37M	-58.24K	-1.73M	-249.00K
Net Income	-1.91M	-3.10M	-785.00K	246.77K	-2.06M	-687.00K
Balance Sheet
Total Assets	68.33K	409.22K	493.81K	1.41M	1.34M	1.89M
Cash, Cash Equivalents and Short-Term Investments	5,110	38.12K	91.17K	271.01K	56.17K	295.93K
Total Debt	1.79M	1.65M	1.14M	2.29M	2.35M	2.79M
Total Liabilities	3.16M	2.51M	1.42M	3.28M	4.08M	2.94M
Stockholders Equity	-3.09M	-2.10M	-926.69K	-1.87M	-2.41M	-1.05M
Cash Flow
Free Cash Flow	-599.29K	-412.94K	-1.42M	112.52K	-202.51K	-192.17K
Operating Cash Flow	-568.05K	-379.98K	-1.39M	112.53K	-184.79K	-135.97K
Investing Cash Flow	-31.24K	-32.97K	2.15M	263.33K	-660.37K	-286.21K
Financing Cash Flow	457.21K	359.89K	-1.28M	-161.02K	605.39K	635.36K

Hypha Labs Risk Analysis

Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We have outstanding shares of Series C Preferred stock held by our sole executive officer that will enable him to control a majority of the total voting power of the Company.Q3, 2024

2.We plan to increase the amount of authorized shares of our common stock and our preferred stock.Q3, 2024

3.Our limited operating history in our current business makes it difficult to evaluate our current business and future prospects and the risk of your investment.Q3, 2024

Hypha Labs Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

FUNI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	56Neutral	$32.40M	-27.85	-8.49%	―	28.04%	43.26%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBS	45Neutral	$5.84M	-0.19	-170.36%	―	38.09%	54.22%
BIAF	43Neutral	$3.73M	-0.02	-257.27%	―	-23.17%	67.18%
FUNI	42Neutral	$376.96K	-0.18	73.84%	―	―	47.23%
ISPC	41Neutral	$2.08M	-0.02	-524.37%	―	-92.11%	86.78%
TRIB	39Underperform	$4.04M	-0.14	48.72%	―	-13.28%	39.65%

* Healthcare Sector Average

Performance Comparison

FUNI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FUNI	Hypha Labs, Inc.	0.01	-0.02	-59.26%
TRIB	Trinity Biotech	6.26	-23.16	-78.72%
PRPO	Precipio	18.10	-1.87	-9.36%
INBS	Intelligent Bio Solutions Inc.	1.76	-7.52	-81.03%
ISPC	Ispecimen Inc	0.82	-29.16	-97.25%
BIAF	bioAffinity Technologies, Inc.	2.91	-31.59	-91.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Feb 18, 2026

Hypha Labs AI Stock Analysis